THU0199 Week 12 Clinical Response to Certolizumab Pegol Predicts Long-Term Outcomes Regardless of Concomitant Medications and Baseline Disease Characteristics in Japanese Patients with Active Rheumatoid Arthritis

Abstract

BackgroundEarly response to certolizumab pegol (CZP), a PEGylated Fc-free anti-TNF, has been shown to predict long-term probability of low disease activity and inhibition of progression of structural joint damage in...